retatrutide type 2 diabetes phase 2 weight loss UK 2026: 3 Results Survodutide vs. Retatrutide for Weight

In this case, a faster titration to the standard 2.5 mg starting dose may be more appropriate

That is why retatrutide keeps getting described as the investigational drug most likely to reshape the obesity market once it reaches a decision point

Do long-term side effects accumulate

Drug class: GIP/GLP-1/Glucagon receptor triagonist Route: Once-weekly subcutaneous injection Developer: Eli Lilly and Company Phase: Phase 3 (TRIUMPH program) Status: Investigational NOT TEY approved by FDA or EMA (despite what your online dealer told you ) Here's how it compares to the drugs most people already know: - Semaglutide (Ozempic/Wegovy): activates 1 receptor GLP-1 - Tirzepatide (Mounjaro/Zepbound): activates 2 receptors GLP-1 + GIP - Retatrutide: activates 3 receptors GLP-1 + GIP + Glucagon That third receptor the glucagon receptor is the differentiator